Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
Sarepta Therapeutics (SRPT) Stock Price & Analysis
2,793 Followers
SRPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.25 - $152.21
Previous Close$132.74
Volume848.97K
Average Volume (3M)898.92K
Market Cap
$12.55B
Enterprise Value$12.27B
Total Cash (Recent Filing)$1.68B
Total Debt (Recent Filing)$1.40B
Price to Earnings (P/E)1996.1
Beta0.75
Next Earnings
Jul 31, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding94,523,766
10 Day Avg. Volume1,125,128
30 Day Avg. Volume898,918
Standard Deviation0.16
R-Squared0.10
Alpha0.00608
Financial Highlights & Ratios
Price to Book (P/B)14.59
Price to Sales (P/S)10.09
Price to Cash Flow (P/CF)-57.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.87
Enterprise Value/Gross Profit8.80
Enterprise Value/Ebitda-26.31
Forecast
1Y Price Target
$168.35Price Target Upside28.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Sarepta Therapeutics News
Bulls Say, Bears Say
Bulls Say
Earnings GrowthSarepta reported its second quarter of profitability, with significant earnings per share.
Market LeadershipSarepta is uniquely positioned to leverage its expertise and market leadership in DMD, with no meaningful near-term competitors.
Regulatory ProgressReceipt of a draft label from the FDA is a very positive signal for Sarepta's Elevidys review.
Bears Say
Commercial PerformanceElevidys' 1Q24 revenue missed the Street consensus and showed flat quarter-over-quarter sales, indicating potential short-term commercial challenges for the product.
Drug Safety ConcernsPfizer's gene therapy for DMD has been linked to cardiac-related SAEs/death, marking a second reported fatality and raising safety concerns among regulators and investors.
Regulatory HurdlesFDA is seen as unlikely to approve the use of Elevidys for non-ambulatory patients without further data, potentially limiting the drug's market expansion and future revenue growth.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $55.25 and its highest was $152.21 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Currently, no data Available
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Jul 31, 2024 which is in 74 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on May 01, 2024. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.013 by $0.357.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -$0.1.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 94,523,766 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $0.37 in its last earnings report, beating expectations of $0.013. Following the earnings report the stock price went down -0.206%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Among the largest hedge funds holding Sarepta Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Sarepta Therapeutics’s shares valued at 117M.
---
Sarepta Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$168.35 (28.14% Upside)
$168.35 (28.14% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 91%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 58.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.99%
12-Months-Change
Fundamentals
Return on Equity
2.02%
Trailing 12-Months
Asset Growth
5.38%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
---
SRPT Earnings Call
Q1 2024
0:00 / 0:00
---
SRPT Stock 12 Month Forecast
Average Price Target
$168.35
▲(28.14% Upside)
Technical Analysis
Best Analysts Covering SRPT
1 Year
1 Year Success Rate
21/25 ratings generated profit
1 Year Average Return
+24.47%
reiterated a buy rating 17 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 84.00% of your transactions generating a profit, with an average return of +24.47% per trade.
---